Last reviewed · How we verify

NCT05691751

Blood Loss Assessment in the Limited Application of Tourniquet During Primary Unilateral TKA

Completed NA Last updated 24 October 2023
What this trial tests

NA trial testing primary unilateral total knee arthroplasty with limited application of tourniquet in Arthritis Knee in 62 participants. Completed in 23 August 2022.

Timeline
1 January 2021
Primary endpoint
23 August 2022
23 August 2022

Quick facts

Lead sponsorDamascus University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment62
Start date1 January 2021
Primary completion23 August 2022
Estimated completion23 August 2022
Sites1 location across Syria

Drugs / interventions tested

Conditions studied

Sponsor

Damascus University

Who can join

Adults 50 to 85, any sex, with Arthritis Knee or Blood Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Tourniquet application in total knee arthroplasty has many benefits and might have a role in the incidence of peri-operative complications the aim of this research: is to look into the effectiveness of the limited application of tourniquet during primary unilateral total knee arthroplasty and compare the perioperative complications with the standard full-time application.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Blood Loss in Primary Unilateral Total Knee Arthroplasty with Limited Tourniquet Application: A Randomized Controlled Trial.
    Diri D, Alasaad H, Abou Ali Mhana S, Muhammed H, et al · · 2023 · cited 5× · PMID 38058509 · DOI 10.2106/jbjs.oa.23.00020

Verify or expand the search:

Other recruiting trials for Arthritis Knee

Currently open trials in the same condition.

Other Damascus University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05691751.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing